In this second part of our focus on ocular diseases, we look at the latest developments taking place in the treatment of central vision disorders such as age-related macular degeneration (AMD). This disease, along with cataracts, diabetic retinopathy, and glaucoma, represents a considerable economic burden to the health systems of developed and developing countries . . . and the situation is predicted to get worse. Read More
Mergers and acquisitions have always been a regular staple in the biotech industry . . . until this year that is. Can it be possible that there won't be at least one blockbuster deal executed by the end of December? Read More
The IPO window has turned into a sliding glass door with biotechs seizing the opportunity to tap the public markets. According to BioWorld Snapshots, 19 biotechs have hit the U.S. markets since the beginning of the year. And there are quite a few others building their books hoping to price in the coming weeks. Read More